- Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised…
- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated…
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland – January 17, 2023 – ImmunOs Therapeutics…